RU2007119989A - Композиции, слитые конструкции и конъюгаты plad домена - Google Patents
Композиции, слитые конструкции и конъюгаты plad домена Download PDFInfo
- Publication number
- RU2007119989A RU2007119989A RU2007119989/13A RU2007119989A RU2007119989A RU 2007119989 A RU2007119989 A RU 2007119989A RU 2007119989/13 A RU2007119989/13 A RU 2007119989/13A RU 2007119989 A RU2007119989 A RU 2007119989A RU 2007119989 A RU2007119989 A RU 2007119989A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- plad
- domain
- drug
- acid sequence
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 3
- 239000003814 drug Substances 0.000 claims 30
- 229940079593 drug Drugs 0.000 claims 28
- 230000004927 fusion Effects 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 238000009510 drug design Methods 0.000 claims 10
- 102000007562 Serum Albumin Human genes 0.000 claims 8
- 108010071390 Serum Albumin Proteins 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 6
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 6
- 102100027207 CD27 antigen Human genes 0.000 claims 6
- 101150013553 CD40 gene Proteins 0.000 claims 6
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 6
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 6
- -1 LT βR Proteins 0.000 claims 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 6
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 6
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 6
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 6
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 6
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 5
- 238000001727 in vivo Methods 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63236104P | 2004-12-02 | 2004-12-02 | |
| US60/632,361 | 2004-12-02 | ||
| GBPCT/GB2005/002163 | 2005-05-31 | ||
| PCT/GB2005/002163 WO2005118642A2 (en) | 2004-06-01 | 2005-05-31 | Bispecific fusion antibodies with enhanced serum half-life |
| GBPCT/GB2005/004319 | 2005-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007119989A true RU2007119989A (ru) | 2009-01-10 |
Family
ID=38792261
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007119989/13A RU2007119989A (ru) | 2004-12-02 | 2005-12-01 | Композиции, слитые конструкции и конъюгаты plad домена |
| RU2007124730/15A RU2411957C2 (ru) | 2004-12-02 | 2005-12-01 | Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007124730/15A RU2411957C2 (ru) | 2004-12-02 | 2005-12-01 | Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090111745A1 (enExample) |
| EP (1) | EP2024396A2 (enExample) |
| JP (1) | JP2008521426A (enExample) |
| KR (1) | KR20070099584A (enExample) |
| CN (1) | CN101111522A (enExample) |
| AU (1) | AU2005311103A1 (enExample) |
| BR (1) | BRPI0518762A2 (enExample) |
| CA (1) | CA2589802A1 (enExample) |
| IL (1) | IL183451A0 (enExample) |
| MX (1) | MX2007006602A (enExample) |
| NO (1) | NO20072670L (enExample) |
| RU (2) | RU2007119989A (enExample) |
| WO (1) | WO2006059110A2 (enExample) |
| ZA (3) | ZA200704431B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1893644A2 (en) * | 2005-06-24 | 2008-03-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors |
| WO2007146163A2 (en) * | 2006-06-09 | 2007-12-21 | Welson Pharmaceuticals, Inc. | Fc-fusion proteins with reduced fc-mediated effector activities |
| EP2144928A2 (en) * | 2007-04-20 | 2010-01-20 | Amgen Inc. | Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor |
| EP2207597B1 (en) * | 2007-09-18 | 2020-02-19 | La Jolla Institute for Allergy and Immunology | Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
| ES2667729T3 (es) * | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| EA027866B1 (ru) | 2009-02-19 | 2017-09-29 | Глэксо Груп Лимитед | Улучшенные связывающие сывороточный альбумин варианты |
| JP2012532619A (ja) | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
| JP2013516967A (ja) | 2010-01-14 | 2013-05-16 | グラクソ グループ リミテッド | 肝臓標的化ドメイン抗体 |
| DK2598526T3 (en) | 2010-07-29 | 2018-11-19 | Eleven Biotherapeutics Inc | CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS |
| EA029793B1 (ru) | 2010-08-23 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ох40 и способы их применения |
| AU2012290379A1 (en) * | 2011-07-29 | 2014-02-06 | Eleven Biotherapeutics, Inc. | Purified proteins |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2013096940A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double binding constructs |
| WO2013096939A1 (en) | 2011-12-23 | 2013-06-27 | Sri International | Selective binding compounds |
| CA2903706C (en) | 2013-03-13 | 2024-01-23 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
| JP6422977B2 (ja) * | 2013-08-30 | 2018-11-14 | エイプリルバイオ カンパニー リミテッド | 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法 |
| AU2018220516B2 (en) * | 2017-02-16 | 2025-03-06 | Sonnet BioTherapeutics, Inc. | Albumin binding domain fusion proteins |
| CN112409480B (zh) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | 结合血清白蛋白的蛋白及其用途 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US12410252B2 (en) | 2021-09-10 | 2025-09-09 | Trustees Of Tufts College | Anti-PD-1 immunoglobulin polypeptides and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| US6479632B1 (en) * | 1988-09-12 | 2002-11-12 | Yeda Research And Development Co. Ltd. | Tumor necrosis factor inhibitory protein and its purification |
| US5811261A (en) * | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
| US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| US7264944B1 (en) * | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| DK0393438T3 (da) * | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
| JPH03164179A (ja) * | 1989-04-21 | 1991-07-16 | Boehringer Ingelheim Internatl Gmbh | Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ |
| US6221675B1 (en) * | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| CA2017025C (en) * | 1989-05-18 | 2008-07-22 | David Wallach | Tumor necrosis factor binding protein ii, its purification and antibodies thereto |
| US6232446B1 (en) * | 1989-05-18 | 2001-05-15 | Yeda Research And Development Co. Ltd. | TNF ligands |
| US6262239B1 (en) * | 1989-05-18 | 2001-07-17 | Yeda Research And Development Co., Ltd. | TNF receptor-specific antibodies |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| WO1998028424A2 (en) * | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| WO2001045746A2 (en) * | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US6843987B2 (en) * | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| WO2001058953A2 (en) * | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| EP1423136A4 (en) * | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| EP3299393A1 (en) * | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558647B1 (en) * | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CN101724071A (zh) * | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
-
2005
- 2005-12-01 BR BRPI0518762-1A patent/BRPI0518762A2/pt not_active IP Right Cessation
- 2005-12-01 MX MX2007006602A patent/MX2007006602A/es unknown
- 2005-12-01 CA CA002589802A patent/CA2589802A1/en not_active Abandoned
- 2005-12-01 AU AU2005311103A patent/AU2005311103A1/en not_active Abandoned
- 2005-12-01 WO PCT/GB2005/004603 patent/WO2006059110A2/en not_active Ceased
- 2005-12-01 KR KR1020077015212A patent/KR20070099584A/ko not_active Withdrawn
- 2005-12-01 RU RU2007119989/13A patent/RU2007119989A/ru not_active Application Discontinuation
- 2005-12-01 CN CNA2005800476820A patent/CN101111522A/zh active Pending
- 2005-12-01 US US11/791,399 patent/US20090111745A1/en not_active Abandoned
- 2005-12-01 EP EP05814076A patent/EP2024396A2/en not_active Withdrawn
- 2005-12-01 RU RU2007124730/15A patent/RU2411957C2/ru not_active IP Right Cessation
- 2005-12-01 JP JP2007543912A patent/JP2008521426A/ja active Pending
-
2007
- 2007-05-25 NO NO20072670A patent/NO20072670L/no not_active Application Discontinuation
- 2007-05-28 IL IL183451A patent/IL183451A0/en unknown
- 2007-05-29 ZA ZA200704431A patent/ZA200704431B/xx unknown
- 2007-06-01 ZA ZA200705010A patent/ZA200705010B/xx unknown
-
2008
- 2008-05-26 ZA ZA200804551A patent/ZA200804551B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007006602A (es) | 2007-12-10 |
| WO2006059110A2 (en) | 2006-06-08 |
| CN101111522A (zh) | 2008-01-23 |
| RU2007124730A (ru) | 2009-01-10 |
| NO20072670L (no) | 2007-08-30 |
| RU2411957C2 (ru) | 2011-02-20 |
| KR20070099584A (ko) | 2007-10-09 |
| EP2024396A2 (en) | 2009-02-18 |
| US20090111745A1 (en) | 2009-04-30 |
| JP2008521426A (ja) | 2008-06-26 |
| ZA200804551B (en) | 2009-11-25 |
| ZA200704431B (en) | 2008-11-26 |
| CA2589802A1 (en) | 2006-06-08 |
| BRPI0518762A2 (pt) | 2008-12-09 |
| IL183451A0 (en) | 2007-09-20 |
| ZA200705010B (en) | 2009-09-30 |
| WO2006059110A3 (en) | 2007-03-15 |
| AU2005311103A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| TWI608015B (zh) | 具有組織標的功能的抗發炎分子 | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2008521426A5 (enExample) | ||
| ES2334773T3 (es) | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. | |
| JP5818804B2 (ja) | ヒトｉｌ−２２ｒａに対するヒト化抗体 | |
| JPH04507195A (ja) | 腫瘍壊死因子結合リガンド | |
| CA3190417A1 (en) | Compositions and methods related to receptor pairings | |
| MX2013010011A (es) | Agentes de unión biespecífica. | |
| US11667704B2 (en) | Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof | |
| JP2008512988A5 (enExample) | ||
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| JPH06501840A (ja) | 多価抗―サイトカイン免疫グロブリン | |
| CN106459190A (zh) | 用于治疗疼痛的化合物和方法 | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| CN110272495A (zh) | 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途 | |
| US7601817B2 (en) | Antibody peg positional isomers, compositions comprising same, and use thereof | |
| TW202214307A (zh) | 奈米脂蛋白－多肽結合物及組成物、系統及其使用方法 | |
| CN100475849C (zh) | p53四聚化结构域介导的四价单链抗体 | |
| JP2005529154A5 (enExample) | ||
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| US20220378925A1 (en) | Conjugated chimeric proteins | |
| JP2022066353A (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| US20240358826A1 (en) | Interleukin-1 alpha chimeric protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100720 |